Seminars in Nephrology
Volume 24, Issue 4 , Pages 379-388 , July 2004

The role of nitric oxide in renal transplantation

  • Ingrid H.C Vos

      Affiliations

    • Department of Pathobiology, Division of Physiology, Faculty of Veterinary Medicine, University Medical Center, Utrecht University, Utrecht, The Netherlands
    • Corresponding Author InformationAddress reprint requests to Ingrid H. C. Vos, PhD, Department of Vascular Medicine, University Medical Center Utrecht, G02.228, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
    • ,
  • Jaap A Joles

      Affiliations

    • Department of Nephrology and Hypertension, Utrecht, The Netherlands
    • ,
  • Ton J Rabelink

      Affiliations

    • Department of Nephrology, Leiden University Medical Center, The Netherlands

References 

  1. Tullius SG, Heemann U, Hancock WW, et al.  Long-term kidney isografts develop functional and morphologic changes that mimic those of chronic allograft rejection. Ann Surg. 1994;220:425–432
  2. Racusen LC, Solez K, Colvin RB, et al.  The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999;55:713–723
  3. Libby P, Pober JS. Chronic rejection. Immunity. 2001;14:387–397
  4. Briscoe DM, Cotran RS. Role of leukocyte-endothelial cell adhesion molecules in renal inflammation (In vitro and in vivo studies). Kidney Int Suppl. 1993;42:S27–S34
  5. Melter M, McMahon G, Fang J, et al.  Current understanding of chemokine involvement in allograft transplantation. Pediatr Transplant. 1999;3:10–21
  6. Abdi R, Tran TB, Sahagun-Ruiz A, et al.  Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol. 2002;13:754–758
  7. Solez K, Racusen LC, Abdulkareem F, et al.  Adhesion molecules and rejection of renal allografts. Kidney Int. 1997;51:1476–1480
  8. Pilmore HL, Yan Y, Eris JM, et al.  Time course of upregulation of fibrogenic growth factors and cellular infiltration in a rodent model of chronic renal allograft rejection. Transpl Immunol. 2002;10:245–254
  9. Joris I, Cuenoud HF, Doern GV, et al.  Capillary leakage in inflammation. A study by vascular labeling. Am J Pathol. 1990;137:1353–1363
  10. Munger KA, Coffman TM, Griffiths RC, et al.  The effects of surgery and acute rejection on glomerular hemodynamics in the transplanted rat kidney. Transplantation. 1993;55:1219–1224
  11. Zayas CF, Guasch A. Early glomerular dysfunction in human renal allografts. Kidney Int. 2001;60:1938–1947
  12. Casanova D, Correas M, Moran JL, et al.  Nitric oxide in cold and warm ischemia reperfusion renal transplantation. Transplant Proc. 2002;34:45–46
  13. Calo L, Marcon R, Rigotti P, et al.  Oxidative stress and nitric oxide system in post-transplant hypertension. Clin Nephrol. 2000;53:6–7
  14. Pilmore HL, Eris JM, Painter DM, et al.  Vascular endothelial growth factor expression in human chronic renal allograft rejection. Transplantation. 1999;67:929–933
  15. Stojanovic T, Grone HJ, Gieseler RK, et al.  Enhanced renal allograft rejection by inhibitors of nitric oxide synthase (A nonimmunologic influence on alloreactivity). Lab Invest. 1996;74:496–512
  16. Schwartz D, Mendonca M, Schwartz I, et al.  Inhibition of constitutive nitric oxide synthase (NOS) by nitric oxide generated by inducible NOS after lipopolysaccharide administration provokes renal dysfunction in rats. J Clin Invest. 1997;100:439–448
  17. Kakoki M, Hirata Y, Hayakawa H, et al.  Effects of tetrahydrobiopterin on endothelial dysfunction in rats with ischemic acute renal failure. J Am Soc Nephrol. 2000;11:301–309
  18. Ishimura T, Fujisawa M, Isotani S, et al.  Endothelial nitric oxide synthase expression in ischemia-reperfusion injury after living related-donor renal transplantation. Transpl Int. 2002;15:635–640
  19. Schramm L, La M, Heidbreder E, et al.  L-arginine deficiency and supplementation in experimental acute renal failure and in human kidney transplantation. Kidney Int. 2002;61:1423–1432
  20. Paul LC, Myllarniemi M, Muzaffar S, et al.  Nitric oxide synthase inhibition is associated with decreased survival of cardiac allografts in the rat. Transplantation. 1996;62:1193–1195
  21. Lee PC, Wang ZL, Qian S, et al.  Endothelial nitric oxide synthase protects aortic allografts from the development of transplant arteriosclerosis. Transplantation. 2000;69:1186–1192
  22. Basset el EA, Berthoux P, Cecillon S, et al.  Hypertension after renal transplantation and polymorphism of genes involved in essential hypertension (ACE, AGT, AT1 R and ecNOS). Clin Nephrol. 2002;57:192–200
  23. Joles JA, Vos IH, Grone HJ, et al.  Inducible nitric oxide synthase in renal transplantation. Kidney Int. 2002;61:872–875
  24. Noiri E, Peresleni T, Miller F, et al.  In vivo targeting of inducible NO synthase with oligodeoxynucleotides protects rat kidney against ischemia. J Clin Invest. 1996;97:2377–2383
  25. Ling H, Gengaro PE, Edelstein CL, et al.  Effect of hypoxia on proximal tubules isolated from nitric oxide synthase knockout mice. Kidney Int. 1998;53:1642–1646
  26. Vos IH, Joles JA, Schurink M, et al.  Inhibition of inducible nitric oxide synthase improves graft function and reduces tubulointerstitial injury in renal allograft rejection. Eur J Pharmacol. 2000;391:31–38
  27. Worrall NK, Boasquevisque CH, Botney MD, et al.  Inhibition of inducible nitric oxide synthase ameliorates functional and histological changes of acute lung allograft rejection. Transplantation. 1997;63:1095–1101
  28. Winlaw DS, Schyvens CG, Smythe GA, et al.  Selective inhibition of nitric oxide production during cardiac allograft rejection causes a small increase in graft survival. Transplantation. 1995;60:77–82
  29. Shears LL, Kawaharada N, Tzeng E, et al.  Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis. J Clin Invest. 1997;100:2035–2042
  30. Koglin J, Glysing-Jensen T, Mudgett JS, et al.  NOS2 mediates opposing effects in models of acute and chronic cardiac rejection (Insights from NOS2-knockout mice). Am J Pathol. 1998;153:1371–1376
  31. Minamoto K, Pinsky DJ. Recipient iNOS but not eNOS deficiency reduces luminal narrowing in tracheal allografts. J Exp Med. 2002;196:1321–1333
  32. Huk I, Nanobashvili J, Neumayer C, et al.  L-arginine treatment alters the kinetics of nitric oxide and superoxide release and reduces ischemia/reperfusion injury in skeletal muscle. Circulation. 1997;96:667–675
  33. Prins HA, Nijveldt RJ, Gasselt DV, et al.  The flux of arginine after ischemia-reperfusion in the rat kidney. Kidney Int. 2002;62:86–93
  34. Muhl H, Pfeilschifter J. Tetrahydrobiopterin is a limiting factor of nitric oxide generation in interleukin 1 beta-stimulated rat glomerular mesangial cells. Kidney Int. 1994;46:1302–1306
  35. Vallance P, Leone A, Calver A, et al.  Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572–575
  36. Fleck C, Janz A, Schweitzer F, et al.  Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients. Kidney Int Suppl. 2001;78:S14–S18
  37. Milstien S, Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite (Implications for vascular endothelial function). Biochem Biophys Res Commun. 1999;263:681–684
  38. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med. 1985;312:159–163
  39. Darley-Usmar V, Halliwell B. Blood radicals (Reactive nitrogen species, reactive oxygen species, transition metal ions, and the vascular system). Pharm Res. 1996;13:649–662
  40. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite (The good, the bad, and ugly). Am J Physiol. 1996;271:C1424–C1437
  41. Noiri E, Nakao A, Uchida K, et al.  Oxidative and nitrosative stress in acute renal ischemia. Am J Physiol. 2001;281:F948–F957
  42. Racasan S, Turkstra E, Joles JA, et al.  Hypoxanthine plus xanthine oxidase causes profound natriuresis without affecting renal blood flow autoregulation. Kidney Int. 2003;64:226–231
  43. Wever RMF, van Dam T, van Rijn HJ, et al.  Tetrahydrobiopterin regulates superoxide and nitric oxide generation by recombinant endothelial nitric oxide synthase. Biochem Biophys Res Commun. 1997;237:340–344
  44. Xia Y, Dawson VL, Dawson TM, et al.  Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. Proc Natl Acad Sci U S A. 1996;93:6770–6774
  45. Mayer B, Werner ER. In search of a function for tetrahydrobiopterin in the biosynthesis of nitric oxide. Naunyn Schmiedebergs Arch Pharmacol. 1995;351:453–463
  46. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature. 1988;333:664–666
  47. Panda K, Rosenfeld RJ, Ghosh S, et al.  Distinct dimer interaction and regulation in nitric-oxide synthase types I, II, and III. J Biol Chem. 2002;277:31020–31030
  48. Stroes E, Kastelein J, Cosentino F, et al.  Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest. 1997;99:41–46
  49. Xia Y, Roman LJ, Masters BS, et al.  Inducible nitric-oxide synthase generates superoxide from the reductase domain. J Biol Chem. 1998;273:22635–22639
  50. Huisman A, Vos I, van Faassen EE, et al.  Anti-inflammatory effects of tetrahydrobiopterin on early rejection in renal allografts (Modulation of inducible nitric oxide synthase). FASEB J. 2002;16:1135–1137
  51. Tiefenbacher CP, Chilian WM, Mitchell M, et al.  Restoration of endothelium-dependent vasodilation after reperfusion injury by tetrahydrobiopterin. Circulation. 1996;94:1423–1429
  52. Albrecht EW, van Goor H, Tiebosch AT, et al.  Nitric oxide production and nitric oxide synthase expression in acute human renal allograft rejection. Transplantation. 2000;70:1610–1616
  53. Attia DM, Verhagen AM, Stroes ES, et al.  Vitamin E alleviates renal injury, but not hypertension, during chronic nitric oxide synthase inhibition in rats. J Am Soc Nephrol. 2001;12:2585–2593
  54. MacMillan-Crow LA, Crow JP, Kerby JD, et al.  Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts. Proc Natl Acad Sci U S A. 1996;93:11853–11858
  55. Dobashi K, Singh I, Orak JK, et al.  Combination therapy of N-acetylcysteine, sodium nitroprusside and phosphoramidon attenuates ischemia-reperfusion injury in rat kidney. Mol Cell Biochem. 2002;240:9–17
  56. Land W, Schneeberger H, Schleibner S, et al.  The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation. 1994;57:211–217
  57. Grimm PC, McKenna R, Nickerson P, et al.  Clinical rejection is distinguished from subclinical rejection by increased infiltration by a population of activated macrophages. J Am Soc Nephrol. 1999;10:1582–1589
  58. Cattell V, Smith J, Jansen A, et al.  Localization of inducible nitric oxide synthase in acute renal allograft rejection in the rat. Transplantation. 1994;58:1399–1402
  59. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol. 1997;15:323–350
  60. Bapat S, Post JA, Braam B, et al.  Visualizing tubular lipid peroxidation in intact renal tissue in hypertensive rats. J Am Soc Nephrol. 2002;13:2990–2996
  61. Colvin RB, Cohen AH, Saiontz C, et al.  Evaluation of pathologic criteria for acute renal allograft rejection (Reproducibility, sensitivity, and clinical correlation). J Am Soc Nephrol. 1997;8:1930–1941
  62. Vos IH, Briscoe DM. Endothelial injury (Cause and effect of alloimmune inflammation). Transpl Infect Dis. 2002;4:152–159
  63. Grone HJ, Weber C, Weber KS, et al.  Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection (blocking monocyte arrest and recruitment). FASEB J. 1999;13:1371–1383
  64. Briscoe DM, Pober JS, Harmon WE, et al.  Expression of vascular cell adhesion molecule-1 in human renal allografts. J Am Soc Nephrol. 1992;3:1180–1185
  65. Baeuerle PA, Baichwal VR. NF-κ B as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv Immunol. 1997;65:111–137
  66. De Caterina R, Libby P, Peng HB, et al.  Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest. 1995;96:60–68
  67. Womer KL, Stone JR, Murphy B, et al.  Indirect allorecognition of donor class I and II major histocompatibility complex peptides promotes the development of transplant vasculopathy. J Am Soc Nephrol. 2001;12:2500–2506
  68. Briscoe DM, Sayegh MH. A rendezvous before rejection (Where do T cells meet transplant antigens?). Nat Med. 2002;8:220–222
  69. Bang A, Speck ER, Blanchette VS, et al.  Recipient humoral immunity against leukoreduced allogeneic platelets is suppressed by aminoguanidine, a selective inhibitor of inducible nitric oxide synthase. Blood. 1996;88:2959–2966
  70. Bang KW, Speck ER, Blanchette VS, et al.  Unique processing pathways within recipient antigen-presenting cells determine IgG immunity against donor platelet MHC antigens. Blood. 2000;95:1735–1742
  71. Del Maschio A, Zanetti A, Corada M, et al.  Polymorphonuclear leukocyte adhesion triggers the disorganization of endothelial cell-to-cell adherens junctions. J Cell Biol. 1996;135:497–510
  72. Fukumura D, Gohongi T, Kadambi A, et al.  Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci U S A. 2001;98:2604–2609
  73. Melter M, Reinders ME, Sho M, et al.  Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood. 2000;96:3801–3808
  74. Leibovich SJ, Chen JF, Pinhal-Enfield G, et al.  Synergistic up-regulation of vascular endothelial growth factor expression in murine macrophages by adenosine A(2A) receptor agonists and endotoxin. Am J Pathol. 2002;160:2231–2244
  75. Kim I, Moon SO, Kim SH, et al.  Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-κ B activation in endothelial cells. J Biol Chem. 2001;276:7614–7620
  76. Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy (The concept of accelerated senescence). J Am Soc Nephrol. 1999;10:167–181
  77. Sijpkens YW, Doxiadis II, De Fijter JW, et al.  Sharing cross-reactive groups of MHC class I improves long-term graft survival. Kidney Int. 1999;56:1920–1927
  78. Racusen LC, Solez K, Colvin RB, et al.  The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999;55:713–723
  79. Romagnani P, Pupilli C, Lasagni L, et al.  Inducible nitric oxide synthase expression in vascular and glomerular structures of human chronic allograft nephropathy. J Pathol. 1999;187:345–350
  80. Albrecht EW, Stegeman CA, Tiebosch AT, et al.  Expression of inducible and endothelial nitric oxide synthases, formation of peroxynitrite and reactive oxygen species in human chronic renal transplant failure. Am J Transplant. 2002;2:448–453
  81. Shahbazi M, Fryer AA, Pravica V, et al.  Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol. 2002;13:260–264
  82. Grone HJ, Simon M, Grone EF. Expression of vascular endothelial growth factor in renal vascular disease and renal allografts. J Pathol. 1995;177:259–267
  83. Nykanen AI, Krebs R, Saaristo A, et al.  Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. Circulation. 2003;107:1308–1314
  84. Zhao XM, Hu Y, Miller GG, et al.  Association of thrombospondin-1 and cardiac allograft vasculopathy in human cardiac allografts. Circulation. 2001;103:525–531
  85. Libby P, Zhao DX. Allograft arteriosclerosis and immune-driven angiogenesis. Circulation. 2003;107:1237–1239
  86. Vos IH, Rabelink TJ, Dorland B, et al.  L-arginine supplementation improves function and reduces inflammation in renal allografts. J Am Soc Nephrol. 2001;12:361–367
  87. Vos IH, Govers R, Grone HJ, et al.  NFκB decoy oligodeoxynucleotides reduce monocyte infiltration in renal allografts. FASEB J. 2000;14:815–822
  88. Castillo J, Berrazueta JR, Herrera L, et al.  Nitric oxide and endothelins are effector agents of hyperacute vascular rejection. Transplant Proc. 1996;28:635
  89. Kelly BS, Alexander JW, Dreyer D, et al.  Oral arginine improves blood pressure in renal transplant and hemodialysis patients. JPEN J Parenter Enteral Nutr. 2001;25:194–202
  90. Andres A, Morales JM, Praga M, et al.  L-arginine reverses the antinatriuretic effect of cyclosporin in renal transplant patients. Nephrol Dial Transplant. 1997;12:1437–1440
  91. Zhang XZ, Ghio L, Ardissino G, et al.  Renal and metabolic effects of L-arginine infusion in kidney transplant recipients. Clin Nephrol. 1999;52:37–43
  92. Zhang XZ, Ardissino G, Ghio L, et al.  L-arginine supplementation in young renal allograft recipients with chronic transplant dysfunction. Clin Nephrol. 2001;55:453–459
  93. Koller-Strametz J, Wolzt M, Fuchs C, et al.  Renal hemodynamic effects of L-arginine and sodium nitroprusside in heart transplant recipients. Kidney Int. 1999;55:1871–1877
  94. Albrecht EW, van Goor H, Joles JA, et al.  Dietary L-arginine attenuates proteinuria and glomerulosclerosis in experimental chronic renal transplant failure (CRTF). Nitric Oxide. 2003;8:53–58

PII: S0270-9295(04)00057-9

doi: 10.1016/j.semnephrol.2004.04.009

Seminars in Nephrology
Volume 24, Issue 4 , Pages 379-388 , July 2004

Article Tools

* Image Usage & Resolution